ClinicalTrials.gg
CompletedNCT00864253Updated Oct 30, 2019Results posted

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

A Phase 3 interventional study of ABI-007 and Dacarbazine in Malignant Melanoma, sponsored by Celgene. Completed at 112 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-30.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
529
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing Albumin-Bound Paclitaxel in Melanoma — none open to participants now, none under way, none of them phase 3. Albumin-Bound Paclitaxel · Melanoma.

Enrollment
Largest of 15
529 · median 30
Started
2009
with 2 others
Phase 3
Only one
of the 16
Registered
8th of 16
by date
Lead sponsor
3 of 16
Celgene

Among the 16 studies testing Albumin-Bound Paclitaxel in Melanoma, this one has the largest enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2009, is the only one in phase 3, and was the 8th registered.

Melanoma

3,372 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 16 studies testing Albumin-Bound Paclitaxel in Melanoma is open now. The open studies under Melanoma, anywhere →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing Albumin-Bound Paclitaxel in Melanoma as a file.
02

Study summary

The main purpose of this research study is to compare the safety, tolerability, and anti tumor activity of an investigational drug, ABI-007 versus Dacarbazine in patients with metastatic melanoma who have not previously received chemotherapy. ABI-007 is a new preparation of the active drug paclitaxel. It contains the same medication as the prescription chemotherapy drug Abraxane®. Abraxane® is approved by the FDA for the treatment of metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Dacarbazine is approved by the FDA for the treatment of melanoma. In this study, ABI-007 and Dacarbazine will be tested as therapy for people who have not yet had any cancer treatment for the diagnosis of metastatic melanoma.

03

Conditions studied

  • Malignant Melanoma

Browse trials for

Keywords

  • Melanoma
  • Malignant
  • Abraxane
  • ABI-007
  • Dacarbazine
  • Dtic-Dome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed cutaneous malignant melanoma with evidence of (Stage IV).
  • No prior cytotoxic chemotherapy for metastatic malignant melanoma is permitted. Prior treatment with kinase inhibitors or cytokines is permitted.
  • No prior cytotoxic chemotherapy is permitted. Prior adjuvant therapy with interferon, Granulocyte-macrophage colony-stimulating factor (GM-CSF) and/or vaccines is permitted.
  • Male or non-pregnant and non-lactating female, and ≥ 18 years of age. If a female patient is of , as evidenced by regular menstrual periods, she must have a negative serum pregnancy test Beta human chorionic gonadotropin (ß-hCG) within 72 hours prior to first study drug administration. If sexually active, the patient must agree to utilize considered adequate and appropriate by the investigator.
  • No other current active within the past 3 years.
  • Radiographically-documented (defined by the presence of at least 1 radiographically documented measurable lesion
  • Patient has the following blood counts at Baseline:
  • (ANC) ≥ 1.5 x 10\^9 cells/L;
  • ≥ 100 x 10\^9 cells/L;
  • (Hgb) ≥ 9 g/dL.
  • Patient has the following blood chemistry levels at Baseline:
  • (AST) glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) ≤ 2.5x (ULN); ≤ 5.0 xULN if hepatic metastases present;
  • total ≤ ULN;
  • creatinine ≤ 1.5 mg/dL.
  • Lactate Dehydrogenase (LDH) ≤ 2.0 x ULNa
  • Expected survival of > 12 weeks.
  • (ECOG) performance status 0-1.
  • Patient or his/her legally authorized representative or guardian has been informed about the nature of the study, and has agreed to participate in the study, and signed the form prior to participation in any study-related activities.

Exclusion criteria

Exclusion Criteria:

  • History of or current evidence of , including .
  • Patient has pre-existing peripheral neuropathy of National Cancer Institute (NCI CTCAE) Scale of Grade ≥ 2.
  • Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
  • Patient has a concurrent illness.
  • Patient is, in the investigator's opinion, unlikely to be able to complete the study through the End of Study (EOS) visit.
  • Patient is currently enrolled, or will enroll in a different clinical study in which therapeutic procedures are performed or investigational therapies are administered while participating in this study. Marker studies or studies evaluating biological correlates are permitted.
  • Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
529 participants (actual)

Study arms

  • Experimental
    ABI-007

    Treatment Arm A (ABI-007): Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.

    Drug: ABI-007

  • Active comparator
    Dacarbazine

    Treatment Arm B (dacarbazine): Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.

    Drug: Dacarbazine

Interventions

  • Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.

    Also known as: Abraxane

  • Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.

    Also known as: Dtic-Dome, DTIC-Dome

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines

    PFS was defined as the time from the randomization date to the start of disease progression or patient death, whichever occurred first. Participants who did not have disease progression or had not died were censored at the last known time that the patient was progression free. In the event of palliative radiotherapy or surgery, they were censored at the last assessment where they were documented to be progression-free prior to the date of radiotherapy or surgery. In follow up, participants who began new anticancer therapy prior to documented progression were censored at the last assessment where they were documented as progression free. Those with two or more missing response assessments prior to a visit with documented disease progression (or death) were censored at the last visit where they were documented to be progression free. RECIST defines progressive disease as a ≥ 20% increase taking as reference the smallest sum of the longest diameters recorded since the treatment began.

    Time frame: Response assessment completed every 8 weeks until disease progression for up to 106 weeks; data cut off 30 June 2012

Secondary outcomes

  1. Participant Survival

    Survival was defined as the time from the date of randomization to the date of death (any cause). Participants were censored at the last known time that they were alive.

    Time frame: Up to 38 months; Up to data cut off of 30 June 2012

  2. Summary of Treatment-emergent Adverse Events (AEs)

    A Treatment Emergent AE (TEAE) was any AE that began or worsened after the start of the study drug through 30 days after the last dose of study drug or end of study whichever is later. A treatment related toxicity was one considered by the investigator to be possibly, probably or definitely related to study drug. AE's were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V 3.0 criteria and the following scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life threatening, and Grade 5 = Death A SAE is any untoward medical occurrence at any dose that is fatal or life threatening, results in persistent or significant disability or incapacity; requires prolonged hospitalizations; is a congenital anomaly birth defect in the offspring of a patient, and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

    Time frame: Maximum exposure to study drug was 106 weeks; up to data cut off of 30 June 2012

  3. Number of Participants Experiencing Dose Reductions, or Dose Interruptions, or Dose Delays of Study Drug

    The number of participants with dose reductions, dose interruptions and dose delays that occurred during the treatment period. Dose reductions, interruptions and delays are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.

    Time frame: Maximum study drug exposure 106 weeks; data cut off 30 June 2012

  4. Nadir for the Absolute Neutrophil Count (ANC) Measurements

    Maximal degree of myelosuppression during study drug dosing was represented by the nadir in ANC measurements over all treatment cycles.

    Time frame: Day 1 up to 106 weeks; up to data cut off 30 June 2012

  5. Nadir for White Blood Cells (WBCs) Measurements

    Maximal degree of myelosuppression was represented by the nadir in white blood cells (WBCs) count measurements over all treatment cycles.

    Time frame: Day 1 up to 106 weeks; up to data cut off 30 June 2012

  6. Nadir for Platelet Count Measurements.

    Maximal degree of myelosuppression was represented by the nadir in platelet count measurements over all treatment cycles.

    Time frame: Day 1 up to 106 weeks; up to data cut off 30 June 2012

  7. Nadir for the Hemoglobin Count Measurements

    Maximal degree of myelosuppression during study drug dosing was represented by the nadir in hemoglobin count measurements over all treatment cycles.

    Time frame: Day 1 up to 106 weeks; up to data cut off 30 June 2012

  8. Pharmacokinetic Parameters

    Time frame: On Cycle 1, Day 1 blood samples were taken at 0.25, 3.5, and 24 hr post-infusion end of the initial dose

Other outcomes

  1. Progression-free Survival (PFS) Based on Investigator Assessment Using RECIST Response Guidelines

    PFS was defined as the time from the randomization date to the start of disease progression or patient death, whichever occurred first. Participants who did not have disease progression or had not died were censored at the last known time that the patient was progression free. In the event of palliative radiotherapy or surgery, they were censored at the last assessment where they were documented to be progression-free prior to the date of radiotherapy or surgery. In follow up, patients who began new anticancer therapy prior to documented progression were censored at the last assessment where they were documented as progression free. Those with two or more missing response assessments prior to a visit with documented disease progression (or death) were censored at the last visit where they were documented to be progression free.

    Time frame: Response assessments completed every 8 weeks until disease progression; up to data cut off 30 June 2012; 38 months

  2. Percent of Participants Who Achieve an Objective Confirmed Complete or Partial Response Based on Blinded Radiology Assessment of Response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0

    RECIST defines complete response (CR): The disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. Disappearance of all non-target lesions. The normalization of tumor marker level confirmed at least 4 weeks after initial documentation. Partial response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits.

    Time frame: every 8 weeks; up to data cut off 30 June 2012

  3. Percent of Participants With Stable Disease (SD) for ≥ 16 Weeks, or Confirmed Complete or Partial Response (i.e., Disease Control) Based on a Blinded Radiology Assessment of Response

    Disease control is stable disease (SD) for \>=16 weeks + complete response (CR) + partial response (PR). See Outcome #4 for definitions of CR and PR. RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.

    Time frame: Response assessment completed every 8 weeks until disease progression; up to data cut-off 30 June 2012

  4. Duration of Response (DOR) in Responding Participants

    Duration of response (DOR) as measured by PFS based on radiological review for participants who achieved an objective confirmed response of CR or PR. DOR was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or participants death from any cause, whichever occurred first. Participants that did not have progression or had not died were censored at the last known time the participant was progression free. Participants that had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) are defined in outcome #4. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

    Time frame: up to data cut off 30 June 2012

07

Results

Posted Jun 5, 2014
Limitations and caveats
Participation in the PK sampling for participants randomized to the ABI-007 arm was optional; too few samples were available to support the analysis

Participant flow

This multicenter study was conducted by investigators in 9 countries: Australia, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom and the United States (US) and treatment was given on an outpatient basis. First participant enrolled 30 April 2011, last participant enrolled June 2011..

Participant flow — Overall Study
MilestoneABI-007 150mg/m^2Dacarbazine 1000mg/m^2
Started264265
Treated257258
Completed165207
Not completed9958
Withdrew: Adverse event5611
Withdrew: Unrelated adverse event31
Withdrew: Physician decision1115
Withdrew: Protocol violation02
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject1818
Withdrew: Death10
Withdrew: Ongoing23
Withdrew: Untreated77

Outcome measures

PrimaryProgression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines

PFS was defined as the time from the randomization date to the start of disease progression or patient death, whichever occurred first. Participants who did not have disease progression or had not died were censored at the last known time that the patient was progression free. In the event of palliative radiotherapy or surgery, they were censored at the last assessment where they were documented to be progression-free prior to the date of radiotherapy or surgery. In follow up, participants who began new anticancer therapy prior to documented progression were censored at the last assessment where they were documented as progression free. Those with two or more missing response assessments prior to a visit with documented disease progression (or death) were censored at the last visit where they were documented to be progression free. RECIST defines progressive disease as a ≥ 20% increase taking as reference the smallest sum of the longest diameters recorded since the treatment began.

Time frame:
Response assessment completed every 8 weeks until disease progression for up to 106 weeks; data cut off 30 June 2012
Reported as:
Median · months
Progression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines
monthsABI-007 150mg/m^2Dacarbazine 1000mg/m^2
Progression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines4.8 (3.7 to 5.5)2.5 (2.0 to 3.6)
Statistical analysis
  • ABI-007 150mg/m^2 vs Dacarbazine 1000mg/m^2 · Log Rank · p = 0.044 (An interim safety review was performed by DMC. An alpha spending function was utilized to preserve the overall Type 1 error at 0.050. The spending function allocated alpha of 0.001 and 0.049 to the interim and final analyses of PFS, respectively.) · Hazard ratio (hr): 0.792 · 95.1% CI 0.631 to 0.992The treatment difference was tested using the stratified log-rank test, stratified by metastatic stage, region, and baseline LDH.
SecondaryParticipant Survival

Survival was defined as the time from the date of randomization to the date of death (any cause). Participants were censored at the last known time that they were alive.

Time frame:
Up to 38 months; Up to data cut off of 30 June 2012
Reported as:
Median · months
Participant Survival
monthsABI-007 150mg/m^2Dacarbazine 1000mg/m^2
Participant Survival12.8 (11.3 to 14.6)10.7 (9.6 to 12.5)
Statistical analysis
  • ABI-007 150mg/m^2 vs Dacarbazine 1000mg/m^2 · Log Rank · p = 0.094 (At the time of the final PFS analysis, an interim analysis of survival was reported. The spending function allocated an alpha of 0.001 and 0.049 for the interim and final analysis, respectively, to preserve the overall Type I error at 0.050.) · Hazard ratio (hr): 0.831 · 99.9% CI 0.578 to 1.196The treatment difference was tested using the stratified log-rank test, stratified by metastatic stage, region, and baseline LDH.
Other pre-specifiedProgression-free Survival (PFS) Based on Investigator Assessment Using RECIST Response Guidelines

PFS was defined as the time from the randomization date to the start of disease progression or patient death, whichever occurred first. Participants who did not have disease progression or had not died were censored at the last known time that the patient was progression free. In the event of palliative radiotherapy or surgery, they were censored at the last assessment where they were documented to be progression-free prior to the date of radiotherapy or surgery. In follow up, patients who began new anticancer therapy prior to documented progression were censored at the last assessment where they were documented as progression free. Those with two or more missing response assessments prior to a visit with documented disease progression (or death) were censored at the last visit where they were documented to be progression free.

Time frame:
Response assessments completed every 8 weeks until disease progression; up to data cut off 30 June 2012; 38 months
Reported as:
Median · months
Progression-free Survival (PFS) Based on Investigator Assessment Using RECIST Response Guidelines
monthsABI-007 150mg/m^2Dacarbazine 1000mg/m^2
Progression-free Survival (PFS) Based on Investigator Assessment Using RECIST Response Guidelines3.7 (3.1 to 3.9)2.1 (1.9 to 2.5)
Statistical analysis
  • ABI-007 150mg/m^2 vs Dacarbazine 1000mg/m^2 · Log Rank · p = 0.086 · Hazard ratio (hr): 0.845 · 95% CI 0.696 to 1.025The treatment difference was tested using the stratified log-rank test, stratified by metastatic stage, region, and baseline LDH.
Other pre-specifiedPercent of Participants Who Achieve an Objective Confirmed Complete or Partial Response Based on Blinded Radiology Assessment of Response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0

RECIST defines complete response (CR): The disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. Disappearance of all non-target lesions. The normalization of tumor marker level confirmed at least 4 weeks after initial documentation. Partial response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits.

Time frame:
every 8 weeks; up to data cut off 30 June 2012
Reported as:
Number · percentage of participants
Percent of Participants Who Achieve an Objective Confirmed Complete or Partial Response Based on Blinded Radiology Assessment of Response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0
percentage of participantsABI-007 150mg/m^2Dacarbazine 1000mg/m^2
Complete Response (CR)00
Partial Response (PR)1511
Statistical analysis
  • ABI-007 150mg/m^2 vs Dacarbazine 1000mg/m^2 · Chi-squared · p = 0.239 · Response rate ratio: 1.305 · 95% CI 0.837 to 2.035
Other pre-specifiedPercent of Participants With Stable Disease (SD) for ≥ 16 Weeks, or Confirmed Complete or Partial Response (i.e., Disease Control) Based on a Blinded Radiology Assessment of Response

Disease control is stable disease (SD) for \>=16 weeks + complete response (CR) + partial response (PR). See Outcome #4 for definitions of CR and PR. RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.

Time frame:
Response assessment completed every 8 weeks until disease progression; up to data cut-off 30 June 2012
Reported as:
Number · percent of participants
Percent of Participants With Stable Disease (SD) for ≥ 16 Weeks, or Confirmed Complete or Partial Response (i.e., Disease Control) Based on a Blinded Radiology Assessment of Response
percent of participantsABI-007 150mg/m^2Dacarbazine 1000mg/m^2
Percent of Participants With Stable Disease (SD) for ≥ 16 Weeks, or Confirmed Complete or Partial Response (i.e., Disease Control) Based on a Blinded Radiology Assessment of Response3927
Statistical analysis
  • ABI-007 150mg/m^2 vs Dacarbazine 1000mg/m^2 · Chi-squared · p = 0.004 · Response rate ratio: 1.442 · 95% CI 1.123 to 1.582
Other pre-specifiedDuration of Response (DOR) in Responding Participants

Duration of response (DOR) as measured by PFS based on radiological review for participants who achieved an objective confirmed response of CR or PR. DOR was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or participants death from any cause, whichever occurred first. Participants that did not have progression or had not died were censored at the last known time the participant was progression free. Participants that had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) are defined in outcome #4. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

Time frame:
up to data cut off 30 June 2012
Reported as:
Median · months
Duration of Response (DOR) in Responding Participants
monthsABI-007 150mg/m^2Dacarbazine 1000mg/m^2
Duration of Response (DOR) in Responding Participants11.1 (7.3 to NA)16.4 (11.0 to 21.8)
Statistical analysis
  • ABI-007 150mg/m^2 vs Dacarbazine 1000mg/m^2 · Log Rank · p = 0.057 · Hazard ratio (hr): 2.201 · 95% CI 0.959 to 5.053
SecondarySummary of Treatment-emergent Adverse Events (AEs)

A Treatment Emergent AE (TEAE) was any AE that began or worsened after the start of the study drug through 30 days after the last dose of study drug or end of study whichever is later. A treatment related toxicity was one considered by the investigator to be possibly, probably or definitely related to study drug. AE's were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V 3.0 criteria and the following scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life threatening, and Grade 5 = Death A SAE is any untoward medical occurrence at any dose that is fatal or life threatening, results in persistent or significant disability or incapacity; requires prolonged hospitalizations; is a congenital anomaly birth defect in the offspring of a patient, and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

Time frame:
Maximum exposure to study drug was 106 weeks; up to data cut off of 30 June 2012
Reported as:
Number · participants
Summary of Treatment-emergent Adverse Events (AEs)
participantsABI-007 150mg/m^2Dacarbazine 1000mg/m^2
≥1 TEAE255239
≥1 TEAE related to study drug250212
≥1 NCI CTCAE Grade (GR) 3 or above167117
≥1 NCI CTCAE GR 3 or above TEAE to study drug12971
≥1 TEAE with outcome of death81
≥1 drug related TEAE with outcome of death21
≥1 serious TEAE6254
≥1 serious TEAE related to study drug2317
≥1 TEAE leading to a dose reduction of study drug8151
≥1 related TEAE leading to dose reduction8049
≥1 TEAE leading to drug interruption416
≥1 drug related TEAE leading to drug interruption315
≥1 TEAE leading to dose delay of study drug12484
≥1 drug related TEAE leading to dose delay10677
≥1 TEAE leading to drug discontinuation5912
≥1 drug related TEAE leading to drug discontinuing5611
SecondaryNumber of Participants Experiencing Dose Reductions, or Dose Interruptions, or Dose Delays of Study Drug

The number of participants with dose reductions, dose interruptions and dose delays that occurred during the treatment period. Dose reductions, interruptions and delays are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.

Time frame:
Maximum study drug exposure 106 weeks; data cut off 30 June 2012
Reported as:
Number · participants
Number of Participants Experiencing Dose Reductions, or Dose Interruptions, or Dose Delays of Study Drug
participantsABI-007 150mg/m^2Dacarbazine 1000mg/m^2
Dose Reductions8151
Dose Interruptions617
Dose Delay145105
SecondaryNadir for the Absolute Neutrophil Count (ANC) Measurements

Maximal degree of myelosuppression during study drug dosing was represented by the nadir in ANC measurements over all treatment cycles.

Time frame:
Day 1 up to 106 weeks; up to data cut off 30 June 2012
Reported as:
Median · 10^9/L
Nadir for the Absolute Neutrophil Count (ANC) Measurements
10^9/LABI-007 150mg/m^2Dacarbazine 1000mg/m^2
Nadir for the Absolute Neutrophil Count (ANC) Measurements1.50 ± 1.5912.40 ± 1.694
SecondaryNadir for White Blood Cells (WBCs) Measurements

Maximal degree of myelosuppression was represented by the nadir in white blood cells (WBCs) count measurements over all treatment cycles.

Time frame:
Day 1 up to 106 weeks; up to data cut off 30 June 2012
Reported as:
Median · 10^9/L
Nadir for White Blood Cells (WBCs) Measurements
10^9/LABI-007 150mg/m^2Dacarbazine 1000mg/m^2
Nadir for White Blood Cells (WBCs) Measurements3.00 ± 1.9344.10 ± 1.968
SecondaryNadir for Platelet Count Measurements.

Maximal degree of myelosuppression was represented by the nadir in platelet count measurements over all treatment cycles.

Time frame:
Day 1 up to 106 weeks; up to data cut off 30 June 2012
Reported as:
Median · 10^9/L
Nadir for Platelet Count Measurements.
10^9/LABI-007 150mg/m^2Dacarbazine Arm B
Nadir for Platelet Count Measurements.228.5 ± 71.40153 ± 92.01
SecondaryNadir for the Hemoglobin Count Measurements

Maximal degree of myelosuppression during study drug dosing was represented by the nadir in hemoglobin count measurements over all treatment cycles.

Time frame:
Day 1 up to 106 weeks; up to data cut off 30 June 2012
Reported as:
Median · g/L
Nadir for the Hemoglobin Count Measurements
g/LABI-007 150mg/m^2Dacarbazine 1000mg/m^2
Nadir for the Hemoglobin Count Measurements109.0 (65.0 to 137)122.0 (65 to 161)
SecondaryPharmacokinetic Parameters
Time frame:
On Cycle 1, Day 1 blood samples were taken at 0.25, 3.5, and 24 hr post-infusion end of the initial dose

No measurements were reported for this outcome.

Adverse events

Collected over Any adverse event (AE) that started at any time from the time the signing of the informed consent to 30 days after the last dose of study drug or End of Study was followed and reported; maximum drug exposure 106 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABI-007 Arm A—62/257 (24.1%)253/257 (98.4%)
Dacarbazine Arm B—54/258 (20.9%)232/258 (89.9%)
Most frequent serious events
Showing 10 of 102
Most frequent serious events
EventABI-007 Arm ADacarbazine Arm B
PyrexiaGeneral disorders2/2575/258
PneumoniaInfections and infestations4/2571/258
CellulitisInfections and infestations3/2574/258
ErysipelasInfections and infestations3/2570/258
Urinary tract infectionInfections and infestations3/2570/258
Small intestinal obstructionGastrointestinal disorders3/2571/258
Febrile neutropeniaBlood and lymphatic system disorders3/2571/258
Peripheral motor neuropathyNervous system disorders2/2570/258
Peripheral sensory neuropathyNervous system disorders2/2570/258
VomitingGastrointestinal disorders2/2572/258
Most frequent other events
Showing 10 of 53
Most frequent other events
EventABI-007 Arm ADacarbazine Arm B
AlopeciaSkin and subcutaneous tissue disorders177/2579/258
FatigueGeneral disorders134/257110/258
NauseaGastrointestinal disorders104/257130/258
DiarrhoeaGastrointestinal disorders103/25745/258
Neuropathy peripheralNervous system disorders98/2576/258
ConstipationGastrointestinal disorders83/25789/258
RashSkin and subcutaneous tissue disorders72/25718/258
Decreased appetiteMetabolism and nutrition disorders68/25752/258
NeutropeniaBlood and lymphatic system disorders66/25763/258
DysgeusiaNervous system disorders62/25724/258

Baseline characteristics

Intent-to-Treat (ITT) Population: The ITT population consisted of all randomized participants regardless of whether the participant received any study drug or had any efficacy assessments collected.

Age, Continuous
Age, Continuous(years)ABI-007 150mg/m^2Dacarbazine Arm B 1000mg/m^2Total
Median62.0 ± 13.4464.0 ± 12.0663.0 ± 12.85
Sex: Female, Male
Sex: Female, Male(Participants)ABI-007 150mg/m^2Dacarbazine Arm B 1000mg/m^2Total
Female9191182
Male173174347
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(participants)ABI-007 150mg/m^2Dacarbazine Arm B 1000mg/m^2Total
0 = Fully Active195181376
1= Restrictive but Ambulatory6882150
2 = Ambulatory but Unable to Work123
3 = Limited Self-Care000
4 = Completely Disabled000
Baseline Lactate Dehydrogenase value
Baseline Lactate Dehydrogenase value(participants)ABI-007 150mg/m^2Dacarbazine Arm B 1000mg/m^2Total
<0.8 * Upper Limit of Normal (ULN)138139277
0.8-1.1 * ULN7269141
>1.1-2 * ULN5156107
>2 * ULN314
Metastatic Stage
Metastatic Stage(participants)ABI-007 150mg/m^2Dacarbazine Arm B 1000mg/m^2Total
M1a272148
M1b6669135
M1c171175346
BRAF Status
BRAF Status(participants)ABI-007 150mg/m^2Dacarbazine Arm B 1000mg/m^2Total
V 600 E6567132
Wild Type (mutation negative)116108224
unknown8390173
08

Study locations

112 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35243, United States
  • AZ Cancer Ctr
    Scottsdale, Arizona 85258, United States
  • Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Genesis Cancer Ctr - Hot Springs
    Hot Springs, Arkansas 71913, United States
  • University of Arkansa for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211, United States
  • San Diego Pacific Oncology and Hematology Associates
    Encinitas, California 92024, United States
  • Loma Linda University Cancer Center
    Loma Linda, California 92354, United States
  • University of Southern California/Norris Cancer Center
    Los Angeles, California 90033, United States
  • University of CA Los Angeles
    Los Angeles, California 90095, United States
  • St. Mary's Medical Center
    San Francisco, California 94117, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Baptist Cancer Institute
    Jacksonville, Florida 32207, United States
  • Lakeland Regional Cancer Center
    Lakeland, Florida 33805, United States
  • University of Miami Hospital and Clincs/SCCC
    Miami, Florida 33136, United States
  • Waren Billhartz Cancer Center
    Maryville, Illinois 62062, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • IA Blood and Cancer Care, PLC
    Cedar Rapids, Iowa 52402, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Saint Louis University
    Saint Louis, Missouri 63110, United States
  • St. John's Medical Research
    Springfield, Missouri 65807, United States
  • Nevada Cancer Institute
    Las Vegas, Nevada 89135, United States
  • Atlantic Melanoma Center
    Morristown, New Jersey 07962, United States
  • Piedmont Hematology
    Winston-Salem, North Carolina 27103, United States
  • OH State University Arthur G. James Cancer Hospital
    Columbus, Ohio 43210, United States
  • Integris Cancer Institute of OK
    Oklahoma City, Oklahoma 73142, United States
  • St. Luke's Hospital & Health Network
    Bethlehem, Pennsylvania 18015, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19131, United States
  • Mary Crowley Research Center
    Dallas, Texas 75246, United States
  • Univ of TX MD Anderson Cancer Ctr
    Houston, Texas 77030, United States
  • Univ of TX Med School at Houston
    Houston, Texas 77030, United States
  • Covenant Health System DBA Joe Arrington Cancer Research and Treatment Center
    Lubbock, Texas 79410, United States
  • Hope Oncology
    Richardson, Texas 75080, United States
  • Utah Cancer Specialist
    Salt Lake City, Utah 84106, United States
  • Univ. of Washington Medical Center/Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Evergreen Hematology & Oncology
    Spokane, Washington 99218, United States
  • Port Macquarie Base Hospital
    Port Macquarie, New South Wales 2444, Australia
  • Royal North Shore Hospital
    Sydney, New South Wales 2065, Australia
  • Sydney West Cancer Trials Centre/Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Royal Adelaide Hospital, Department of Medical Oncology
    Adelaide, South Australia 5000, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Sir Charles Gairdner Hospital
    Nedlands Perth, Western Australia, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • BCCA Centre for the Southern Interior
    Kelowna, British Columbia V1Y 5L3, Canada
  • BCCA, Centre for the Southern Interior
    Kelowna, British Columbia V1Y 5L3, Canada
  • BC Cancer Agency-Fraser Valley Ctr.
    Surrey, British Columbia V3V 1Z2, Canada
  • BC Cancer Agency-Vancouver
    Vancouver, British Columbia V5Z4E6, Canada
  • BC Cancer Agency-Vancouver Island Ctr.
    Victoria, British Columbia V8R 6V5, Canada
  • London Regional Cancer Program
    London, Ontario N6A 4L6, Canada
  • Credit Valley Hospital
    Missiauga, Ontario L5M 2N1, Canada
  • The Ottawa Hospital Regional Cancer Centre
    Ottawa, Ontario K1H 8L6, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • McGill University Dept. of Oncology Clinical Research Program
    Montreal, Quebec H2W 1S6, Canada
  • Hopital Saint Andre' CHU de Bordeaux
    Bordeaux, 33075, France
  • Centre Hospitaller Universitaire de Grenoble
    Grenoble Cedex 09, 38043, France
  • CHRU Hopital Claude Huriez
    Lile Cedax, France
  • Hopital Dypuytren-CHU de Limoges
    Limoges cedex, France
  • Centre Leon Berad
    Lyon, France
  • Hopital Sainte Marguerite
    Marseille Cedex 9, France
  • CHU Hopital Saint Eloi
    Montepellier Cedex 5, France
  • Centre Regional Val d' Aurelle Paul Lamarque
    Montpellier, 34298, France
  • Hopital de 1 Archet 2
    Nice Cedex 3, 06200, France
  • Hopital Saint-Louis
    Paris Cedex, France
  • Hopital Bichat
    Paris, 75018, France
  • Groupe hospitalier Cochin-St. Vincent de Paul
    Paris, France
  • Institut Gustave Roussy (IGR) Centre de Lutte Contre le Canc
    Villejuif Cedex, 94805, France
  • Charite Universitaetsmedizin Berlin
    Berlin, BE 10117, Germany
  • Universitaetsklinkum Heidelberg
    Heidelberg, BW, Germany
  • Universitaetsklinkum Heidelberg
    Heidelber, BW, Germany
  • Universitaetsklinkum Tuebingen
    Tuebingen, BW 72076, Germany
  • Universitaetsklinkum Wuerzburg PS
    Wuerzburg, BY 97080, Germany
  • Universitaetsklinkum Hamburg-Eppendorf
    Hamburg, HH, Germany
  • Univeritaetsklinkum Goettingen
    Gottington, NI, Germany
  • Medizinische Hochschuke Hannover
    Hannover, NI 30625, Germany
  • St. Josef-Hospital
    Bochum, Northwest 44791, Germany
  • Universitaetsklinkum Essen
    Essen, Northwest, Germany
  • Universitaetklinkum Koeln
    Koln, Northwest, Germany
  • Universitaetsklinkum Schegwig-Holstein
    Keil, SH 24105, Germany
  • Universitaetsklinkum Dresden
    Dresden, SN, Germany
  • UniversitawtsklinKum Jena
    Jena, Strasse 35 07743, Germany
  • Universitaesklinkum Leipzig
    Leipzig, Germany
  • Universitaetsklinkum Mainz
    Mainz, Germany
  • Istituto Tumori "Giovanni Paolo II"
    Bari, BA, Italy
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei T
    Meldola, FC 47014, Italy
  • IST-Istituto Nazionale per la Ricera sul Cancro
    Genova, GE 16132, Italy
  • Istituto Europeo di Oncologia
    Milano, MI 20141, Italy
  • Istituto Nazionale Tumori
    Milano, MI, Italy
  • IOV-Instituto Oncologico IRCCS
    Padova, PD 35128, Italy
  • Azienda Ospedaliera Universitaria Sense
    Siena, SI 53100, Italy
  • Ist. Naz. per lo studio e la cura dei tumori G. Pascale
    Napoli, 80131, Italy
  • Ospedale S. Chiara
    Pisa, 56100, Italy
  • Medisch Centrum Alkmaar
    Alkmaar, 1815, Netherlands
  • Rijnstate ziekenhuis Arnhem
    Amhem, 6800TA, Netherlands
  • Erasmus MC ae" Daniel den Hoed
    Rotterdam, Netherlands
  • H Clinic i Provincial
    Barcelona, 08036, Spain

Showing the first 100 of 112 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma. Ann Oncol. 2015 Nov;26(11):2267-74. doi: 10.1093/annonc/mdv324. Epub 2015 Sep 26. PubMed 26410620 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2009 to primary completion in Jun 2012, 37 months.

Results were first posted in Jun 2014, 2 years after primary completion. A results delay was requested in Aug 2013.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 37 months is close to that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2009
First posted
Mar 18, 2009
StartActual
Apr 23, 2009
Primary completionActual
Jun 1, 2012
CompletionActual
Feb 12, 2014
Results delay requested
Aug 6, 2013
Results first posted
Jun 5, 2014
Last update
Oct 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00864253
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Mar 18, 2009
Start date
Apr 23, 2009
Primary completion
Jun 1, 2012
Completion
Feb 12, 2014
Results posted
Jun 5, 2014
Last update
Oct 30, 2019

Study contacts

Evan Hersh, MD
principal investigator · University of Arizona
Ileana Elias, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion